Secondary failure (n = 4) | Patients with successful long-term maintenance (n = 6) | p-value | |
---|---|---|---|
Age, mean (SD), years | 60.75 ± 6.7 | 41.8 ± 15.23 | < 0.05 |
Female, n (%) | 2 (50%) | 4 (66.7%) | NS |
Disease duration, mean (SD), years | 15 ± 14.07 | 7.8 ± 4.35 | NS |
TCZ exposure before tapering, months (SD) | 19.5 ± 7.23 | 14.8 ± 7.5 | NS |
Remission achievement delay, months (SD) | 3.5 ± 3.4 | 2.16 ± 2.4 | NS |
Remission duration, months (SD) | 8 ± 5.7 | 4.8 ± 2.13 | NS |
RF positive, n (%) | 3 (75%) | 2 (33.3%) | NS |
ACPA positive, n (%) | 3 (75%) | 2 (33.3%) | NS |
Erosive status, n (%) | 4 (100%) | 4 (66.7%) | NS |
Previous number of sDMARDs | 2.75 ± 1.25 | 2 ± 0.63 | NS |
Previous number of bDMARDs | 1.5 ± 1.73 | 1.66 ± 1.21 | NS |
Swollen joint count | 0 | 0.166 ± 0.4 | NS |
Tender joint count | 2.25 ± 2.6 | 3.16 ± 4.57 | NS |
Hyperhemia at Doppler | 1 (25%) | 1 (16.7%) | NS |
Number of patients with active synovitis | 1 (25%) | 4 (66.7%) | NS |
Number of active synovitis | |||
Hands | 8 | 4 | NS |
Feet | 0 | 5 | NS |
Concomitant therapy | |||
MTX, n (%) | 2(50%) | 2(33.3%) | NS |
LEF, n (%) | 0(0%) | 2 (33.3%) | NS |
DAS28; mean (SD) | 1.48 ± 1.1 | 1.51 ± 1.05 | NS |
ESR, mm/h; mean (SD) | 7.5 ± 11 | 6.66 ± 10.1 | NS |
CRP, mg/L, mean (SD) | 2.55 ± 3.3 | 3 ± 1.87 | NS |
TCZ plasma level, mg/L; mean (SD) | 7.12 ± 7.7 | 7.35 ± 6.41 | NS |
ADAb positivity | 0 | 0 | NS |
Flare, mean (SD) | 2 ± 0 | 1 ± 0.9 | 0.07 |